Yahoo · Nov 3, 2026
Pfizer Inc. Q3 2026 Earnings Call Summary
Moby summary of Pfizer Inc.'s Q3 2026 earnings call
NYSE · BHVN
Biohaven Ltd.
Healthcare · Biotechnology
$15.61
Down-$0.37 (-2.37%)
Updated Nov 4, 2026, 10:00 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.21B
- P/E ratio
- -1.55
- Dividend yield
- 0.00%
- 52-week range
- $8.03 – $18.24
- Volume
- 2.02M
- Avg. volume
- 3.75M
Price performance · BHVN
BHVN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BHVN closed at $15.61 after 21 trading sessions, up 29.22% for the selected period.
- Last close
- $15.61
- Period change
- +29.22%
- Period low
- $10.78
- Period high
- $16.49
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $15.46 | $16.09 | $15.25 | $15.61 | 2.02M |
| Nov 2, 2026 | $15.98 | $16.105 | $15.08 | $15.16 | 2.59M |
| Oct 30, 2026 | $15.46 | $16.33 | $15.12 | $15.42 | 3.16M |
| Oct 29, 2026 | $15.46 | $16.49 | $15.46 | $16.49 | 2.45M |
| Oct 28, 2026 | $15.11 | $15.87 | $14.955 | $15.52 | 3.15M |
| Oct 27, 2026 | $14.44 | $15.30 | $14.13 | $15.29 | 2.43M |
| Oct 26, 2026 | $13.94 | $14.6973 | $13.695 | $14.45 | 2.68M |
| Oct 23, 2026 | $15.215 | $15.37 | $13.83 | $13.88 | 4.69M |
| Oct 22, 2026 | $16.10 | $16.54 | $14.45 | $14.69 | 30.51M |
| Oct 21, 2026 | $11.90 | $12.1647 | $11.625 | $11.75 | 1.44M |
| Oct 20, 2026 | $11.35 | $11.845 | $11.07 | $11.81 | 1.53M |
| Oct 19, 2026 | $11.01 | $11.52 | $10.865 | $11.35 | 1.69M |
| Oct 16, 2026 | $11.31 | $11.40 | $10.70 | $10.78 | 2.42M |
| Oct 15, 2026 | $10.95 | $11.66 | $10.94 | $11.43 | 1.45M |
| Oct 14, 2026 | $11.39 | $11.50 | $10.82 | $10.93 | 1.78M |
| Oct 13, 2026 | $11.79 | $11.79 | $11.16 | $11.42 | 2.43M |
| Oct 12, 2026 | $11.91 | $11.99 | $11.65 | $11.81 | 1.62M |
| Oct 9, 2026 | $11.90 | $12.27 | $11.745 | $12.08 | 1.37M |
| Oct 8, 2026 | $11.83 | $12.12 | $11.46 | $11.93 | 2.7M |
| Oct 7, 2026 | $11.86 | $12.2318 | $11.845 | $11.88 | 2.15M |
| Oct 6, 2026 | $13.00 | $13.04 | $11.88 | $12.08 | 3.05M |
Latest BHVN news
The latest Smart Investors Daily articles mentioning BHVN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BHVN research
Overview
Company profile and research snapshot.
Company profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2026 | Morgan Stanley | Overweight | — |
| Oct 30, 2026 | Canaccord Genuity | Buy | — |
| Oct 23, 2026 | RBC Capital | Sector Perform | — |
| Sep 10, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 8, 2026 | RBC Capital | Sector Perform | — |
News briefing
Generated Nov 4, 2026, 9:10 PM
Why Is BHVN Down Today?
Biohaven Ltd. (BHVN) is trading down $0.37 (2.37%) despite receiving a positive analyst price target revision, suggesting broader market headwinds or profit-taking may be overshadowing the bullish catalyst. The disconnect between the upward analyst revision and today's price decline reflects the complexity of biotech investing, where sentiment shifts can occur independent of fundamental improvements.
Bottom line: Biohaven's mixed signals today—a solid 10.16% analyst price target increase offset by a 2.37% stock decline—suggest investors should focus on underlying fundamentals rather than daily volatility. Watch for upcoming clinical data, commercial execution updates, and whether the new $24.48 consensus price target gains traction as the next potential catalyst for the stock to re-rate higher.
Fintel · Nov 2, 2026
Biohaven Consensus Price Target Increased 10.16% to $24.48
Benzinga · Oct 30, 2026
Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.
Yahoo · Oct 30, 2026
Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?
Biohaven (BHVN) reported a narrower quarterly net loss alongside new preclinical data on its BHV-1420 program in membranous nephropathy, giving investors two concrete updates to weigh on earnings and pipeline progress. Biohaven’s latest updates landed after a strong run, with a 1-day share price return of 6.25% and a 30-day share price return of 24.08% helping push the year to date share price return to 52.12%. This comes even as the 1-year total shareholder return declined 5.18% and the...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
